Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings. Gaithersburg, MD and Vienna, Austria (September 18, 2024) — Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials,...
Synthgene Biotechnology, Areterna’s parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial...
Recently, Synthgene Biotech (hereinafter referred to as “Synthgene”), Areterna’s parent company, received a confirmation letter from the United States Food and Drug Administration (FDA) for one of our core mRNA raw material products – CAP5 – which have...
FOR IMMEDIATE RELEASE Gaithersburg, MD (July 2nd, 2024) — Areterna LLC, a company with a mission to democratize mRNA vaccine by supplying low-cost GMP raw materials, today announced plans to offer veterinary mRNA vaccine development service to its customers in the US...
FOR IMMEDIATE RELEASE Areterna LLC, a subsidiary of Synthgene Biotech renowned for providing top-tier raw materials and services catering to mRNA and oligonucleotide therapeutics, has signed a global distribution agreement with BIORON GmbH, a premium manufacturer and...
FOR IMMEDIATE RELEASE Areterna LLC, a subsidiary of Synthgene Biotech, established for the purpose of providing raw materials and services tailored to mRNA and oligonucleotide therapeutics, has entered into a global distribution agreement with Medsol Corporation, a...
